市場調查報告書
商品編碼
1271789
下一代測序 (NGS) 市場——按產品、按應用、按類型、按技術、按最終用途和預測,2023-2032 年Next Generation Sequencing Market - By Product, By Application, By Type, By Technology, By End-use & Forecast, 2023 - 2032 |
由於其在各種製藥和生物製藥應用中的使用越來越多,預計到 2032 年,下一代測序 (NGS) 市場將出現顯著增長。
擁有尖端生物技術解決方案的新興經濟體正在使用 NGS 進行藥物發現和開發。 新疾病的出現和尚未確定治愈方法的終末期疾病的頻繁發生,增加了對先進治療方法的需求。 例如,NGS 已成為臨床腫瘤學和癌症診斷的關鍵工具。 NGS能夠以超高的靈敏度和精度檢測突變,為癌症診斷和治療提供突破。
視網膜母細胞瘤 (RB)、肺癌診斷等是 NGS 發展勢頭強勁的突出領域。 據美國癌症協會估計,到2023年,美國將有超過23.83萬例肺癌新發病例和超過12.7萬例死亡病例。 領先的生物技術和製藥公司正在 NGS 的幫助下加速癌症診斷和治療領域的創新和發展。
例如,2023 年 1 月,Thermo Fisher Scientific 宣佈為用於治療非小細胞肺癌患者的靶向抗癌藥物 Tagrisso 設計基於固體組織和血液的伴隨診斷 (CDx) 測試。與阿斯利康的合作夥伴關係。 兩家公司將利用 Oncomine Dx Express Test,它具有智能樣本到報告的工作流程,可使用完全集成的 NGS 平台 Genexus Dx 系統在 24 小時內提供測試結果。 因此,行業參與者之間更多的合作和新產品的發布將推動市場的增長。
按產品分類,它分為服務、設備、消耗品和其他。 其中,由於各種 NGS 服務的可用性,服務行業預計從 2023 年到 2032 年將以超過 18% 的複合年增長率增長。 最近在寡聚合成服務、全基因組測序、宏基因組學解決方案、癌症分析服務、RNA 測序等方面取得的突破使人們能夠獲得新的 NGS 服務。
按類型劃分,市場分為靶向測序、全基因組測序 (WGS)、外顯子組測序等。 預計在預測期內,靶向測序的需求將激增,因為它可以準確測量患者的基因庫。 個性化療法在治療危及生命的疾病方面的日益普及進一步促進了靶向測序的使用,以研究個體的基因構成。
就最終用途而言,它分為製藥/生物技術、學術機構/研究中心和醫院/診所。 到 2022 年,製藥和生物技術公司的 NGS 市場規模將達到 10 億美元。 製藥公司開發先進療法來應對複雜疾病的壓力越來越大,這推動了 NGS 技術的採用。 世界各地的生物技術公司都依賴 NGS 來生產生物產品和新藥。
按地區劃分,由於印度和中國醫療基礎設施建設取得進展,預計到 2032 年亞太地區 NGS 市場規模將超過 100 億美元。 此外,基因組測序的成本、WGS 的技術進步以及亞太地區研發設施和研究中心的增加預計將推動該行業的增長。
Next-generation sequencing (NGS) market is set to witness substantial growth through 2032 owing to the increasing use of the technology for diverse pharmaceutical & biopharmaceutical applications.
Developed economies worldwide with state-of-the-art biotech solutions are using NGS for drug discovery and development. The emergence of novel diseases and the high prevalence of terminal illnesses with no promising cure have fueled the need for advanced therapies. For instance, NGS has emerged as a pivotal tool in clinical oncology and cancer diagnostics. It helps detect variants at an ultra-sensitive and precise level, offering groundbreaking cancer diagnosis and care.
Retinoblastoma (RB), and lung cancer diagnosis are some of the prominent areas where NGS has gained momentum. As per the American Cancer Society's 2023 estimates, the U.S. is projected to have more than 238,300 new cases of lung cancer and mortality of over 127,000 deaths. Leading biotech and pharma companies are accelerating innovation and development in the field of cancer diagnostics therapeutics with the help of NGS.
For instance, in January 2023, Thermo Fisher Scientific announced a partnership with AstraZeneca to design a solid tissue & blood-based companion diagnostic (CDx) test for Tagrisso, a targeted cancer drug used to treat patients with non-small cell lung cancer. The duo will use a fully-integrated NGS platform, Genexus Dx System to access the Oncomine Dx Express Test, featuring smart specimen-to-report workflow offering test results within 24 hours. As a result, a growing collaboration between industry players and new product launches will augment market growth.
In terms of product, the industry is classified into services, instruments, consumables, and others. Among these, the services segment will grow at over 18% CAGR between 2023 and 2032 led by the availability of a wide variety of NGS services. Recent breakthroughs in oligo synthesis services, whole genome sequencing, metagenomics solutions, cancer analysis services, RNA sequencing, and others are enabling access to novel NGS services.
Based on type, the market is segmented into targeted sequencing, whole genome sequencing (WGS), exome sequencing, and others. Targeted sequencing is set to witness an upsurge in demand over the forecast years due to its ability to measure a patient's gene pool precisely. The growing popularity of personalized therapeutics in the treatment of life-threatening diseases is further driving the use of targeted sequencing to study an individual's genetic makeup.
With regard to end-use, the industry is classified into pharmaceutical & biotech, academic institutes & research centers, and hospitals & clinics. NGS market size from pharmaceutical & biotechnology companies was USD 1 billion in 2022. The increasing pressure on pharma companies to develop highly advanced therapeutics to tackle complex disorders will fuel the adoption of NGS technologies. Biotech firms worldwide are using NGS to produce biological goods and novel pharmaceuticals.
From a regional frame of reference, the Asia Pacific NGS market size will exceed USD 10 billion by 2032 due to the rise in healthcare infrastructure development across India, and China. Additionally, promising cost of genome sequencing, technological breakthroughs in WGS, and the increasing number of R&D facilities and research centers in APAC will propel industry growth.